PT-141 vs Kisspeptin: Two Approaches to Sexual Function Research

PT-141 (Bremelanotide) and Kisspeptin represent two distinct peptide approaches to sexual function — one acting through the melanocortin system centrally, the other through the hypothalamic GnRH axis.

PT-141: Central MC4R Activation

PT-141 (cyclic heptapeptide, non-selective melanocortin receptor agonist) acts primarily through MC4R in the medial preoptic area (MPOA) and limbic structures, increasing sexual motivation and arousal independently of genital vasculature. This differs fundamentally from PDE5 inhibitors, which act peripherally on penile/vaginal blood flow.

FDA Approval: Vyleesi (bremelanotide, 1.75 mg SC) was approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The pivotal RECONNECT trial (Kingsberg SA et al., *Obstetrics & Gynecology*, 2019) showed statistically significant improvements in FSFI desire subscale and FSDS-DAO distress scores in women who self-administered before anticipated sexual activity.

Kisspeptin: GnRH Axis Activation With Central Effects

Kisspeptin acts on Kiss1R (kisspeptin receptor) on GnRH neurons — the primary physiological driver of pulsatile GnRH release, gateway to LH, FSH, testosterone, and oestrogen production. Kiss1R is also expressed in limbic areas, enabling direct central sexual motivation effects.

Dhillo WS et al. at Imperial College London (*Journal of Clinical Investigation*, 2007): kisspeptin administration to healthy male volunteers increased LH significantly via GnRH stimulation AND increased brain activation in limbic regions (cingulate cortex, hippocampus) on fMRI — with responses greater for erotic vs non-erotic visual stimuli in the kisspeptin group.

Comninos AN et al. (*Nature Communications*, 2017) in 29 men with hypogonadotropic hypogonadism: kisspeptin infusion partially restored sexual behaviour and function scores — attributed to both GnRH-stimulatory hormonal restoration and direct CNS sexual motivation effects.

Mechanism Comparison

PT-141 is appropriate for research on acute central arousal; Kisspeptin for research on the GnRH axis and hormonal regulation of sexual function. Gonadorelin (synthetic GnRH) acts downstream of kisspeptin's target, directly at the pituitary.

PT-141 is FDA-approved for HSDD in premenopausal women; kisspeptin is a research compound.

<!-- deep-links-v1 -->

Related Hormonal and Sexual Health Peptides

PT-141 and Kisspeptin operate within a broader landscape of peptides studied for hormonal and reproductive health. Triptorelin, a GnRH superagonist, is used in research for gonadotropin axis manipulation — the opposite hormonal approach from kisspeptin's pulse-stimulating mechanism. Leuprolide, another GnRH agonist, provides the established clinical reference point for hypothalamic-pituitary-gonadal axis suppression studies. Cetrorelix and Degarelix are GnRH antagonists that offer immediate gonadotropin suppression without the initial flare seen with agonists, useful as mechanistic comparators. Thyrotropin (TSH) is referenced in the context of multi-axis hormonal research where thyroid and gonadal health intersect. Oxytocin, the bonding and reproductive hormone, has documented effects on sexual behavior and arousal in animal models that parallel PT-141's central mechanisms. Testagen, a testicular bioregulator tetrapeptide, is studied for testosterone secretion support in male gonadal health research. Chitomur, a bladder and prostate bioregulator, addresses urogenital health in male models. Prostamax, a prostate bioregulator, is studied for its effects on prostate tissue function and androgen receptor signaling in aging male research.